Graduate School of Medicine. Each of the 34 institution fulfilled the institutional criteria for performing PCI proposed by the Ministry of Health, Labour, and Welfare and each hospital annually performs more than 100 cases of PCI. The mean follow-up period was 1,219±184 days in M group and 1,235±180 days in P group. This study was approved by the local ethics committee on human research (Gifu University, Japan).
Definition of Low-Risk CAD and ACS
We defined low-risk CAD as 1-or 2-vessel disease excluding ostial lesions of the LAD, and high-risk CAD patients had 3-vessel disease, LMT lesions or ostial lesions of the LAD. ACS was defined as a case of acute myocardial infarction or unstable angina requiring emergency cardiac catheterization; that is, patients who underwent elective PCI for uncontrollable angina in M group or for restenosis after PCI in P group were not designated as ACS patients.
Definition of the Severity of Angina Symptoms
We classified the severity of angina symptoms into 5 grades using the modified Canadian Cardiovascular Society classification (Table 1) .
Statistical Analysis
The percentages of patients progressing to the primary endpoints of cardiac death or ACS in each treatment group were compared using Kaplan-Meier estimates. Time courses to cardiac death or cardiac death/ACS are presented using Kaplan-Meier curves. Averaged age and changes in the severity score of angina were compared between the M and P groups using 1-way analysis of variance (Bonferroni/ Dunn), and if the difference was significant, a modified unpaired t-test was used to assess if it was significantly different. All values are expressed as mean ± SD. A p value less than 0.05 was regarded as significant. Other outcomes were compared using chi-square test.
Results

Background of Patients
Age, gender, grade of initial symptoms and number of lesion vessels were similar between the 2 groups ( Table 2 ). The distribution of underlying diseases was similar, particularly for previous myocardial infarction (old myocardial infarction: ≈30% in both groups; Table 3 ). There was no significant difference in medication (Table 4) .
Treatment Course
During follow-up of 3.4 years, 172 of the 190 patients (90.6%) in M group continued to be treated with medication only, but additional PCI was needed in the other 18 patients (9.4%). Additional PCI and/or coronary artery bypass grafting was significantly more frequent in P group (64 of the 192 patients: 33.2%; p<0.05). One year later, the severity of angina symptoms was well improved in both groups (Table 5) .
Mortality Rate
During the 3.4-year follow-up, 26 patients died: 15 of 190 patients (7.9%) in M group and 11 of 192 patients (5.7%) in p group. The rates of cardiac death were similar (3 of 190 patients in M (1.6%); 5 of 192 patients in P (2.6%); Fig 1) . The rate of noncardiac death was significantly greater in the M group (12 of 190 patients (6.3%): 2 renal failure, 2 pneumonia, 1 systemic lupus erythematosus, 1 malignant lymphoma, 1 pancreatic cancer, and 5 unknown) than in the P group (6 of 192 patients (3.1%): 2 pneumonia, 1 renal failure, 1 suicide, 1 gastric cancer, 1 unknown).
The overall rate of cardiac death and ACS was 2.1% (4 of 190 patients) in M group and 4.7% (9 of 192 patients) in P group, which was not a significant difference. The incidence of ACS was similar between the 2 groups (1 of 190 M patients: 0.53%; 4 of 192 P patients; 2.1%).
Total Cost During the First and Second Year
Total cost per patient in the M and P groups during the first year was 863,540±1,259,840 yen and 3,756,450± 2,274,700 yen, respectively, and 365,760±476,750 yen and 1,115,750±621,020 yen during the following year. The total cost per patient was markedly cheaper in the M group, 4.4-fold cheaper during the first year and 3.1-fold during the second year (Fig 2) . 
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Discussion
Prognosis and Treatment Costs of Japanese Patients With Low-Risk CAD
The present study demonstrated that even in Japanese patients (1) anginal attacks in patients with low-risk CAD can be mostly controlled by medical therapy alone and (2) there was no significant difference between medical-preceding therapy and PCI-preceding therapy in the cardiac death rate (1.6% and 2.6%, respectively) or the rate of cardiac death + ACS (2.1 and 4.7%, respectively). The lack of significance may be due to the small number of the patients (total number: 382 patients), but the estimated number of patients in which the difference between the 2 groups becomes significant is 166,000 and 24,000, respectively. This suggests that the prognosis may be almost similar between the 2 types of therapy. In particular, the slope of the Kaplan-Meier curves for the 2 groups became almost the same more than 200 days after treatment, although the incidence of event was higher in the PCI-preceding group within the first 200 days after treatment. The 2 groups were treated with similar drugs and had similar underlying diseases and risk factors. Therefore, the increase in cardiac death and ACS within the 200 days would depend on acute or chronic restenosis after PCI. Anyway, PCI does not affect the long-term prognosis of low-risk CAD. These findings confirm the previous data in Western trials such as the ACME 2 and RITA-2 3 trials.
In the present study, the long-term prognosis of low-risk CAD was very good, compared with that of RITA-2 in which the incidence of cardiac death/ACS in the average follow-up period of 2.7 years was 3.3% in the medicalpreceding group and 6.3 in the PCI-preceding group. 3 It is unknown whether this is related to Japanese patients with low-risk CAD having milder coronary atherosclerosis than patients from Western countries or the recent progression of drugs such as statins, angiotensin-receptor blockers and/or intervention devices such as stents. In addition, the difference in the medical insurance systems in Japan and Western countries may be important.
We previously reported that the ratio of coronary angiography to patients with CAD in Japan is estimated to be approximately 1.4-fold that in the United State. 5 Moreover, PCI devices are much more expensive in Japan. 6, 7 We found that the total cost per patient in the M group was lower than that in the P group, which confirms previous published data from Western countries. 2, 3 
Study Limitations
In the present study, randomization was retrospectively performed using consecutive patients with low-risk CAD treated by medical-preceding therapy selected by consensus between the doctor and patient, although the long-term outcomes were surveyed prospectively for an average of 3.4 years. Therefore, the most important limitation is that the subjects were not general patients with low-risk CAD. This feature is reflected in the higher incidence of noncardiac death in the M group. In addition, the improvement of anginal symptoms in the short term after treatment was not examined, although it was reported to be better in the P group in RITA-2. 3 To date, PCI-preceding therapy has generally been preferred in Japanese hospitals, but no large-scale trials that can provide adequate evidence have been performed in Japan. Therefore, in the "Guidelines for the indications for intervention treatment for cardiovascular disease" (chairman: Hisayoshi Fujiwara, Gifu University) 4 there are no comments on whether low-risk stable angina on effort should be treated with medical-preceding or PCIpreceding therapy. Thus, a prospective and randomized trial at registration is warranted.
Conclusion
Medical-preceding therapy in patients with low-risk CAD may be more advantageous than PCI-preceding therapy from the perspective of long-term prognosis and medical economy.
